Lombard Medical (OTCMKTS: EVARF) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Earnings & Valuation

This table compares Lombard Medical and Ocular Therapeutix’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lombard Medical $12.17 million 0.32 -$31.03 million ($1.54) -0.09
Ocular Therapeutix $1.89 million 86.61 -$44.70 million ($2.27) -2.45

Lombard Medical has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lombard Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lombard Medical has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Lombard Medical and Ocular Therapeutix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lombard Medical 0 0 0 0 N/A
Ocular Therapeutix 0 2 4 0 2.67

Ocular Therapeutix has a consensus target price of $20.67, suggesting a potential upside of 271.70%. Given Ocular Therapeutix’s higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Lombard Medical.

Profitability

This table compares Lombard Medical and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lombard Medical N/A N/A N/A
Ocular Therapeutix -2,976.48% -148.76% -86.68%

Insider & Institutional Ownership

39.9% of Lombard Medical shares are owned by institutional investors. Comparatively, 52.9% of Ocular Therapeutix shares are owned by institutional investors. 26.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Lombard Medical beats Ocular Therapeutix on 7 of the 13 factors compared between the two stocks.

About Lombard Medical

Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive News & Ratings for Lombard Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical and related companies with MarketBeat.com's FREE daily email newsletter.